SEC Form 4 · accession 0000899243-18-007642
Eledon Pharmaceuticals, Inc. · ELDN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Catherine C. Turkel
Officer — President
Period of report
Mar 13, 2018
Accepted (ET)
Mar 15, 2018 · 6:46 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001404281
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 13, 2018 | A | 20,000 | $0.00 | A | 44,519 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $4.83 | Mar 13, 2018 | A | 24,000 | A | — | Mar 13, 2028 | Common Stock | 24,000 | 24,000 | D |
Explanation of responses
- F1This represents restricted stock units representing the right to receive shares of the Issuer's Common Stock, which will vest in full on the later of achievement of a performance-related goal or the first anniversary of the grant date.
- F2This option represents a right to purchase a total of 24,000 shares of the Issuer's Common Stock, one quarter of which will become fully vested and exercisable on March 13, 2019, with the remaining 18,000 shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.